COEP

Coeptis Therapeutics Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$102.06M
P/E Ratio
EPS
$-2.81
Beta
-0.43
52W High
$21.41
52W Low
$6.80
50-Day MA
$12.26
200-Day MA
$13.58
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Coeptis Therapeutics Inc

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and markets brand-name and generic pharmaceuticals and cell therapy platforms for cancer patients. The company is headquartered in Wexford, Pennsylvania.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$1.36M
Gross Profit (TTM)$1.18M
EBITDA$-11.86M
Operating Margin-230.70%
Return on Equity-136.90%
Return on Assets-65.10%
Revenue/Share (TTM)$0.32
Book Value$2.36
Price-to-Book7.53
Price-to-Sales (TTM)74.88
EV/Revenue70.42
EV/EBITDA-0.64
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)1564.00%
Shares Outstanding$6.22M
Float$5.25M
% Insiders13.64%
% Institutions9.00%

Historical Volatility

HV 10-Day
117.25%
HV 20-Day
126.64%
HV 30-Day
114.00%
HV 60-Day
93.41%
HV Rank

Volatility is currently expanding

Latest News

Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application

~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol “ZSQR”.

GlobeNewsWire4/7/2026Neutral

More HEALTHCARE Stocks

Data last updated: 4/27/2026